Key result
Higher circulating visfatin linked to ~82% higher odds of symptomatic carotid disease.
Why the study?
Visfatin is a pro-inflammatory adipokine overexpressed in unstable plaques, but its utility as a circulating biomarker of high-risk intraplaque features, ultrasound-assessed carotid stenosis, and symptomatic disease in patients undergoing carotid endarterectomy was uncertain.
Does circulating visfatin predict ultrasound-assessed carotid stenosis and symptomatic disease in patients with severe carotid disease undergoing carotid endarterectomy?
Observational (n=206)
Does circulating visfatin predict ultrasound-assessed carotid stenosis and symptomatic disease in patients with severe carotid disease undergoing carotid endarterectomy?
Answers are grounded in this paper and cite their sources.
Circulating visfatin independently predicts both ultrasound-assessed carotid stenosis and symptomatic status in patients undergoing carotid endarterectomy, suggesting its utility as a biomarker for plaque instability and symptom risk.
Introduction Atherosclerotic carotid disease is a major cause of stroke and transient ischemic attacks. Visfatin, a pro-inflammatory adipokine, is overexpressed in unstable plaques. This study assessed whether circulating visfatin serves as a biomarker of plaque intraplaque high-risk features and ultrasound-assessed carotid stenosis in patients with severe carotid disease undergoing carotid endarterectomy (CEA). Methods In patients undergoing carotid endarterectomy, preoperative blood samples and carotid plaques were collected for histological characterization of intraplaque features. Plasma visfatin was quantified using ELISA. Participants were classified as either symptomatic (recent ipsilateral ischemic stroke within the prior 30 days) and as asymptomatic (no recent cerebrovascular event). Outliers were excluded using predefined boxplot-based criteria. Group differences were assessed using the Mann-Whitney test, correlations with Spearman’s R, and associations with individual outcomes were examined using linear and logistic regression models adjusted for clinical, biochemical, and histological covariates. Results The final cohort included 37 symptomatic and 169 asymptomatic patients, with no significant differences in age or sex. Symptomatic patients had greater ultrasound-assessed stenosis (80% vs. 75%, p = 0.035). Circulating visfatin correlated with ultrasound-assessed stenosis (ρ = 0.232, p = 0.001) and with features of plaque instability (Figure 1). In adjusted linear regression, visfatin independently associated with ultrasound-assessed stenosis (β = 1.30, 95% CI: 0.28–2.32, p = 0.013; Figure 2A), although this was not confirmed when adjusting for intraplaque features (Figure 2B). Logistic regression showed that visfatin independently predicted symptomatic disease after adjustment for clinical variables (OR = 1.27, 95% CI: 1.04–1.56, p = 0.021; Figure 2C) and after further adjustment for intraplaque features (OR = 1.82, 95% CI: 1.79–2.99, p = 0.010; Figure 2D). Conclusions Circulating visfatin predicts both ultrasound-assessed carotid stenosis and symptomatic disease in patients with severe carotid stenosis undergoing CEA. Visfatin may represent a promising biomarker for future studies evaluating plaque progression and symptom risk, including those involving patients with earlier stages of carotid atherosclerosis.
No takes yet. Share an insight, caveat, or question.
Tirandi et al. (2026) conducted an observational in Severe atherosclerotic carotid stenosis undergoing carotid endarterectomy (n=206). Circulating plasma visfatin vs. Asymptomatic patients / lower visfatin levels was evaluated on Symptomatic carotid disease (recent ipsilateral ischemic stroke within the prior 30 days) and ultrasound-assessed carotid stenosis (OR 1.82, 95% CI 1.79-2.99, p=0.010). Circulating visfatin independently predicted symptomatic carotid disease and ultrasound-assessed stenosis in endarterectomy patients.
Synapse has enriched 10 related papers. Consider them for comparative context: